CUTISS give people access to personalised skin therapies, offering solutions to those effected by deep skin defects. denovoSkinTM brings a new face to the skin graft industry due to the innovative research undertaken by CUTISS.
Composed mainly by an outer epidermis and an inner dermis, skin is our interface to the outer world and its total loss would result in death. If a large portion of the epidermis and dermis are lost it would result in full-thickness defects (FTSD), a sometimes unsolvable, problem for surgeons.
denovoSkinTM a personalised bio-engineering dermo-epidermal skin grafts offers a solution to the lack of permanent skin coverage DenovoSkinTM, the Advanced Therapy Medicinal Product (ATMP) developed at CUTISS, is made of cells isolated from a stamp-sized patient’s split thickness biopsy and it comprises both an epidermal and a dermal components.
Funded by Horizon 2020, CUTISS AG has been awarded an SME Instrument Phase 2 grant of €2.5m under grant agreement, the full title of the project that started in 2018 is: “Personalised, bioengineered skin grafts for the permanent treatment of skin defects.”
CUTISS is a spin-off company founded at the University of Zurich (UZH) and was incorporated in March 2017. Until then, denovoSkinTM was developed at the Tissue Biology Research Unit (TBRU), a laboratory associated with the Department of Surgery of the University Children’s Hospital in Zurich, Switzerland, where close collaboration between scientists and surgeons was envisioned to be the ideal substrate to succeed.
CUTISS’ team now comprises of 17 people participating in the research and development, automation, production, and Clinical Trials of personalised tissue therapy – a very strong team that works in close relation with clinical, regulatory and engineering partners.
